AXONIS Therapeutics, Inc., an emerging biotechnology company advancing breakthrough research to develop therapies for neurological disorders, today announced it has secured an additional $5 million in funding. This financing round, which follows last year’s $4 million seed round, was led by Alexandria Venture Investments with participation by R3 Bio, BoxOne Ventures and Civilization Ventures and two leading spinal cord injury non-profit foundations, the Christopher & Dana Reeve Foundation and Spinal Research, joined by current investors. The new investment will support AXONIS’ next development phase as it continues to advance its novel neuromodulating technology into the clinic.
In connection with the Company’s operational launch in early 2020, it secured $4 million in seed funding from a group of angel investors. The Company has also received several non-dilutive funding awards, including from the Massachusetts Life Sciences Center and NIH Small Business Innovation Research program, and was a recipient of two Golden Tickets, one each from Boehringer Ingelheim and Astellas Pharma.